Korea Institute of Toxicology (KIT)
Government-funded Korean research institute providing GLP nonclinical safety studies, including inhalation toxicology, safety pharmacology and reproductive toxicity.
10 contract research organizations in our directory list both GLP Toxicology and Non-human Primate among their capabilities, across 6 countries. 10 report GLP capability and 3 report AAALAC accreditation. Confirm species-specific experience with each lab when you get in touch.
Showing 10 CROs. Order rotates daily so no lab is permanently listed first.
Government-funded Korean research institute providing GLP nonclinical safety studies, including inhalation toxicology, safety pharmacology and reproductive toxicity.
Vertically integrated nonhuman primate CRO in South Carolina combining on-site breeding with discovery pharmacology, GLP toxicology, vaccine and gene therapy studies.
Large China-based nonclinical CRO offering GLP safety assessment, pharmacology, pharmacokinetics and bioanalysis, with operations in China and the United States.
Independent German preclinical CRO conducting GLP toxicology, reproductive toxicology, carcinogenicity and safety pharmacology studies across rodent and non-rodent species.
Korean non-clinical CRO offering IND and NDA-enabling GLP toxicology, including general, reproductive and genetic toxicity, carcinogenicity and safety pharmacology, with NHP capacity through its group companies.
Shanghai-based nonclinical CRO with GLP safety evaluation, pharmacology, DMPK, bioanalysis and biomarker services for small molecules, biologics and cell and gene therapies, operating several sites in China.
Long-established Japanese CRO with large GLP nonclinical safety facilities and deep nonhuman primate experience, supporting toxicology, safety pharmacology and pharmacokinetics.
Hyderabad-based preclinical CRO offering GLP toxicology, pharmacology and pharmacokinetic studies across rodent and non-rodent species.
Beijing-based preclinical CRO focused on GLP safety evaluation, with branches across China and support for biologics, nucleic acid and cell and gene therapies.
Korean nonhuman primate CRO in the Biotoxtech group with GLP repeat-dose toxicity and cardiovascular safety pharmacology in NHPs, plus NHP inhalation studies.